New CAR-T therapy triples remission time for patients with multiple myeloma

A recent Phase II trial, published in the New England Journal of Medicine, has demonstrated that a new type of CAR-T therapy, called idecabtegene vicleucel (ide-cel), more than triples the expected length of remission for multiple myeloma patients who have relapsed several times. The researchers from UT Southwestern Medical Center (TX, USA) investigated 128 patients across nine sites in the USA, one in Canada and ten in Europe, ages 18 and older, who had previously been given regimens from the three main classes of treatment. The patients received a median of six previous antimyeloma regimens and 120 had undergone stem...